TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Apogee Therapeutics
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Apogee Therapeutics reported positive Phase 1 trial results for APG333, a novel half-life extended TSLP antibody, demonstrating a 55-day half-life and potential for quarterly dosing in respiratory treatments.

Insights
BACpN   neutral

Buffett is gradually selling Bank of America stock due to increased valuation and changing interest rate environment, suggesting a pragmatic investment approach


APGE   positive

Successful clinical trial results with promising data on drug half-life, potential dosing frequency, and safety profile